Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: Report of a randomized study - Cancer and Leukemia Group B 8642

Journal of Clinical Oncology

Volumn 17, Issue 5, 1999, Pages 1397-1406

  Costanza, Mary E ^a   Weiss, Raymond B ^a   Henderson, I Craig ^a   Norton, Larry ^a   Berry, Donald A ^a   Cirrincione, Constance ^a   Winer, Eric ^a   Wood, William C ^a   Frei III, Emil ^a   McIntyre, O Ross ^a   Schilsky, Richard L ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMONAFIDE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ELSAMICIN A; FLUOROURACIL; MELPHALAN; TRIMETREXATE; TRIMETREXATE GLUCURONATE;

ADOLESCENT; ADULT; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; TREATMENT OUTCOME;

EID: 0032954658     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.5.1397     Document Type: Article

References (51)

1. Sledge GW Jr, Amman KH: Progress in chemotherapy for metastatic breast cancer. Semin Oncol 19:317-332, 1992
2. Jones S, Winer E, Vogel C, et al: Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 13:2567-2574, 1995
3. Nabholtz JM, Thuerlimann B, Beswoda WR, et al on behalf of the International 304 Study Group: Taxotere (T) improves survival over mitomycin C vinblastine (MV) in patients (PTS) with metastatic breast cancer (MBC) who have failed an anthracycline (ANT) containing regimen: Final results of a phase III randomized trial. Proc Am Soc Clin Oncol 17:101a, 1998 (abstr 390)
4. Hoogstraten B: Adriamycin (NSC-123127) in the management of advanced breast cancer: Studies of the Southwest Oncology Group. Cancer Chemother Rep 6:329-334, 1975
5. Muss H, Van Echo D, Korzun AH, et al: Esorubicin (4′-deoxydoxorubicin, NSC 267469) in advanced breast cancer. Am J Clin Oncol 13:333-337, 1990
6. Simon R, Wittes RE, Ellenberg SS: Randomized phase II clinical trials. Cancer Treat Rep 69:1375-1381, 1985
7. Wittes RE, Marsoni S, Simon R, et al: The phase II trial. Cancer Treat Rep 69:1235-1239, 1985
8. Chlebowski RT, Lillington LM: A decade of breast cancer clinical investigation: Results as reported in the Program/Proceedings of the American Society of Clinical Oncology. J Clin Oncol 12:1789-1795, 1994
9. Baker LH, Vaughn BC, Al-Sarraf M, et al: Evaluation of combination vs sequential cytotoxic chemotherapy in the treatment of advanced breast cancer. Cancer 33:513-518, 1974
10. Tormey D, Carbone P, Band P: Breast cancer survival in single and combination chemotherapy trials since 1968. Proc Am Assoc Cancer Res 18:64, 1977 (abstr 254)
11. Lemkin SR, Dollinger MR: Combination vs single drug therapy in advanced breast cancer. Proc Am Assoc Cancer Res 14:37, 1973 (abstr 145)
12. Chlebowski RT, Irwin LE, Pugh RP, et al: Survival of patients with metastatic breast cancer treated with either combination or sequential chemotherapy. Cancer Res 39:4503-4506, 1979
13. Canellos GP, Pocock SJ, Taylor SG, et al: Combination chemotherapy for metastatic breast carcinoma: Prospective comparison of multiple drug therapy with L-phenylalanine mustard. Cancer 38:1882-1886, 1976
14. Mouridsen HT, Palshof T, Brahm M, et al: Evaluation of single-drug vs multiple-drug chemotherapy in the treatment of advanced breast cancer. Cancer Treat Rep 61:47-50, 1977
15. Sledge GW Jr, Neuberg D, Ingle S, et al: Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer (MBC): An intergroup trial. Proc Am Soc Clin Oncol 16:1a, 1997 (abstr)
16. Costanza ME: Phase II studies: Untreated breast cancer patients. J Natl Cancer Inst 84:1833, 1992
17. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of taxol, an active agent in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991
18. Talbot DC, Smith IE, Mansi JL, et al: Anthrapyrazole CI941: A highly active new agent in the treatment of advanced breast cancer. J Clin Oncol 9:2141-2147, 1991
19. Canobbio L, Boccardo F, Pastorino G, et al: Phase-II study of Navelbine in advanced breast cancer. Semin Oncol 16:33-36, 1989 (suppl 4)
20. Cornbleet MA, Stuart-Harris RC, Smith IE, et al: Mitoxantrone for the treatment of advanced breast cancer: Single-agent therapy in previously untreated patients. Eur J Cancer Clin Oncol 20:1141-1146, 1984
21. Kolaric K, Vukas D: Carboplatin activity in untreated metastatic breast cancer: A phase II trial. Proc Am Soc Clin Oncol 9:26, 1990 (abstr)
22. Neri B, Pacini P, Bartalucci S, et al: Epirubicin high-dose therapy in advanced breast cancer: Preliminary clinical data. Int J Clin Pharmacol Ther Toxicol 27:388-391, 1989
23. Sledge GW, Loehrer PJ, Roth BJ, et al: Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol 6:1811-1814, 1988
24. Bertino JR, Sawicki WL, Moroson BA, et al: 2,4-Diamino-5-methyl-6-[(3,4,5-trimethoxganilino)methyl]quinazoline (tmq), a potent non-classical folate antagonist inhibitor. I. Effect on dihydrofolate reductase and growth of rodent tumors in vitro and in vivo. Biochem Pharmacol 28:1983-1987, 1979
25. Kamen BA, Eibl B, Cashmore AR, et al: Efficacy and transport of a new lipid soluble antifol, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanlino)methyl]quinazoline (TMQ: JB-11) in methotrexate resistant cells. Proc Am Assoc Cancer Res 22:26, 1981 (abstr)
26. Diddens H, Niethammer D, Jackson RC: Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate and CB 3717 in human lymphoma and osteosarcoma cells resistant to methotrexate. Cancer Res 43:5286-5292, 1983
27. Legha S, Tenney D, Ho DH, et al: Phase I clinical and pharmacology study of trimetrexate. Proc Am Soc Clin Oncol 4:48, 1985 (abstr)
28. Stewart JA, McCormack JJ, Tong W, et al: Phase I clinical and pharmacokinetic study of trimetrexate using a daily ×5 schedule. Cancer Res 48:5029-5035, 1988
29. Olver IN, Bishop JF, Raghavan D, et al: Phase I study of trimetrexate as a five day continuous infusion. Med Pediatr Oncol 15:151, 1987
30. Fanucchi MP, Walsh TD, Fleisher M, et al: Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks. Cancer Res 47:3303-3308, 1987
31. Brana MF, Castellano JM, Roldan CM, et al: Synthesis and modes of action of a new series of imide derivatives of 3-nitro-1,8-naphthalic acid. Cancer Chemother Pharmacol 4:61-66, 1980
32. Waring MJ, Gonzalez A, Jimenez A, et al: Intercalative binding to DNA of antitumor drugs derived from 3-nitrol-1,8-naphthalic acid. Nucleic Acids Res 7:217-230, 1979
33. Hsiang YU, Jiang JB, Liu LF: Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs. Mol Pharmacol 35:371-376, 1989
34. Felder TB, McLean MA, Vestal ML, et al: Pharmacokinetics and metabolism of the antitumor drug amonafide (NSC-308847) in humans. Drug Metab Dispos 15:773-778, 1987
35. Saez R, Craig JB, Kuhn JG, et al: Phase I clinical investigation of amonafide. J Clin Oncol 7:1351-1358, 1989
36. Leiby JM, Malpeis L, Staubus AE, et al: Amonafide (NSC 308847): A clinical phase I study of two schedules of administration. Proc Am Assoc Cancer Res 29:278, 1988 (abstr)
37. Legha SS, Ring S, Raber M, et al: Phase I clinical investigation of benzisoquinolinedione. Cancer Treat Rep 71:1165-1169, 1987
38. Calvert AH, Harland SJ, Newell DR, et al: Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 9:140-147, 1982
39. Leyvraz S, Ohnuma T, Lassau M, et al: Phase I study of carboplatin in patients with advanced ovarian cancer, intermittent intravenous bolus, and 24-hour infusion. J Clin Oncol 3:1385-1392, 1985
40. Koeller JM, Trump DL, Tutsch KD, et al: Phase I clinical trial and pharmacokinetics of carboplatin (NSC 241240) by single monthly 30-minute infusion. Cancer 57:222-225, 1986
41. Van Echo DA, Egorin MJ, Whitacre MY, et al: Phase I clinical and pharmacologic trial of carboplatin daily for 5 days. Cancer Treat Rep 68:1103-1114, 1984
42. Lam KS, Veitch JA, Forenza S, et al: Biosynthesis of Elsamicin A, a novel antitumor antibiotic. J Nat Prod 52:1015-1021, 1989
43. Schurig JE, Bradner WT, Basler GA, et al: Experimental antitumor activity of BMY-28090, a new antitumor antibiotic. Invest New Drugs 7:173-178, 1989
44. Tanis BC, Vermorken JB, Ten Bokkel Huinink WW, et al: Phase I study of Elsamicin (BMY-28090). Proc Am Soc Clin Oncol 9:71, 1990 (abstr)
45. Raber M, Amato R, Sumrall C, et al: Phase I clinical trial of elsamitrucin. Proc Am Assoc Cancer Res 31:178, 1990 (abstr)
46. La Crete FP, Langer C, Walczak J, et al: Phase I/pharmacokinetic study of elsamitrucin (BMY-28090, NSC 369 327) in patients with advanced cancer. Proc Am Soc Clin Oncol 9:72, 1990 (abstr)
47. Ratain MJ, Mick R, Berezin F, et al: Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin Pharmacol Ther 50:573-579, 1991
48. Ratain MJ, Mick R, Berezin F, et al: Phase I study of amonafide dosing based on acetylator phenotype. Cancer Res 53:2304-2308, 1993
49. Dawson NA, Costanza ME, Korzun A, et al: Trimetrexate in untreated and previously treated patients with metastatic breast cancer: A Cancer and Leukemia Group B study. Med Pediatr Oncol 19:283-288, 1991
50. Costanza ME, Berry D, Henderson IC, et al: Amonafide: An active agent in the treatment of previously untreated advanced breast cancer. A Cancer and Leukemia Group B study (CALGB 8642). Clin Cancer Res 1:699-704, 1995
51. Costanza ME, Henderson IC, Berry D, et al: A randomized comparison of single agent induction chemotherapy vs standard chemotherapy for stage IV breast cancer: CALGB 8642. Proc Am Soc Clin Oncol 14:104, 1995 (abstr)